Jacobi Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $563K | Buy |
1,134
+40
| +4% | +$17.7K | 0.03% | 428 |
|
|
2026
Q1 | $489K | Buy |
1,094
+33
| +3% | +$15.4K | 0.03% | 420 |
|
|
2025
Q4 | $481K | Buy |
1,061
+19
| +2% | +$8.19K | 0.03% | 417 |
|
|
2025
Q3 | $408K | Buy |
1,042
+56
| +6% | +$23.4K | 0.02% | 435 |
|
|
2025
Q2 | $439K | Buy |
986
+22
| +2% | +$10.1K | 0.03% | 411 |
|
|
2025
Q1 | $467K | Hold |
964
| – | – | 0.03% | 372 |
|
|
2024
Q4 | $388K | Sell |
964
-34
| -3% | -$15.8K | 0.03% | 402 |
|
|
2024
Q3 | $464K | Buy |
998
+74
| +8% | +$35.5K | 0.04% | 368 |
|
|
2024
Q2 | $433K | Buy |
924
+24
| +3% | +$10.4K | 0.04% | 341 |
|
|
2024
Q1 | $376K | Buy |
900
+8
| +0.9% | +$3.38K | 0.03% | 350 |
|
|
2023
Q4 | $363K | Buy |
892
+82
| +10% | +$30.3K | 0.04% | 343 |
|
|
2023
Q3 | $282K | Hold |
810
| – | – | 0.03% | 359 |
|
|
2023
Q2 | $285K | Hold |
810
| – | – | 0.03% | 364 |
|
|
2023
Q1 | $255K | Sell |
810
-270
| -25% | -$81K | 0.03% | 369 |
|
|
2022
Q4 | $312K | Buy |
1,080
+134
| +14% | +$40.8K | 0.04% | 332 |
|
|
2022
Q3 | $274K | Hold |
946
| – | – | 0.04% | 342 |
|
|
2022
Q2 | $267K | Buy |
+946
| New | +$253K | 0.04% | 356 |
|
|
2021
Q4 | – | Sell |
-356
| Closed | -$65K | – | 1314 |
|
|
2021
Q3 | $65K | Sell |
356
-117
| -25% | -$22.8K | 0.01% | 597 |
|
|
2021
Q2 | $95K | Buy |
473
+140
| +42% | +$29.3K | 0.01% | 504 |
|
|
2021
Q1 | $72K | Buy |
333
+3
| +0.9% | +$659 | 0.01% | 505 |
|
|
2020
Q4 | $78K | Buy |
330
+11
| +3% | +$2.52K | 0.01% | 453 |
|
|
2020
Q3 | $87K | Buy |
319
+62
| +24% | +$17.1K | 0.02% | 403 |
|
|
2020
Q2 | $75K | Buy |
257
+6
| +2% | +$1.63K | 0.01% | 406 |
|
|
2020
Q1 | $60K | Buy |
251
+164
| +189% | +$37.6K | 0.01% | 396 |
|
|
2019
Q4 | $19K | Hold |
87
| – | – | ﹤0.01% | 641 |
|
|
2019
Q3 | $15K | Hold |
87
| – | – | ﹤0.01% | 668 |
|
|
2019
Q2 | $16K | Hold |
87
| – | – | ﹤0.01% | 668 |
|
|
2019
Q1 | $16K | Hold |
87
| – | – | ﹤0.01% | 632 |
|
|
2018
Q4 | $14K | Hold |
87
| – | – | ﹤0.01% | 614 |
|
|
2018
Q3 | $17K | Hold |
87
| – | – | ﹤0.01% | 615 |
|
|
2018
Q2 | $15K | Hold |
87
| – | – | ﹤0.01% | 641 |
|
|
2018
Q1 | $14K | Hold |
87
| – | – | ﹤0.01% | 641 |
|
|
2017
Q4 | $14K | Hold |
87
| – | – | ﹤0.01% | 616 |
|
|
2017
Q3 | $14K | Hold |
87
| – | – | ﹤0.01% | 579 |
|
|
2017
Q2 | $11K | Hold |
87
| – | – | ﹤0.01% | 557 |
|
|
2017
Q1 | $10K | Buy |
87
+31
| +55% | +$2.73K | 0.01% | 466 |
|
|
2016
Q4 | $5K | Sell |
56
-31
| -36% | -$2.52K | ﹤0.01% | 508 |
|
|
2016
Q3 | $8K | Buy |
87
+56
| +181% | +$5.29K | ﹤0.01% | 503 |
|
|
2016
Q2 | $3K | Buy |
+31
| New | +$2.68K | ﹤0.01% | 610 |
|
Other funds holding VRTX
WF
Jacobi Capital Management's VRTX Position: Q2 2026 in Review
Jacobi Capital Management increased its Vertex Pharmaceuticals (VRTX) stake by 3.7% in Q2 2026, buying an estimated $17.7K and bringing the position to 1,134 shares worth $563K. The position accounts for 0.03% of the portfolio, ranked #428.
Jacobi Capital Management first reported a position in VRTX in Q2 2016 and has held it in 39 quarters since. 734 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Jacobi Capital Management held 1,134 shares of Vertex Pharmaceuticals worth $563K as of Q2 2026.
- Jacobi Capital Management bought 40 Vertex Pharmaceuticals shares in Q2 2026, an estimated $17.7K.
- Vertex Pharmaceuticals made up 0.03% of Jacobi Capital Management's portfolio in Q2 2026, its #428 holding.
- Jacobi Capital Management first reported a position in Vertex Pharmaceuticals in Q2 2016 and has held it in 39 quarters since.
- 734 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Jacobi Capital Management's 13F filing for Q2 2026, filed 31 Jul 2026.